Biodesix pushes Nodify lung evidence

Biodesix is trying to move the Nodify Lung story out of the lab and into hospital operations. That is the real news here. On May 11, the company said its ATS 2026 presentations will focus on real-world use and healthcare-system economics, not just whether a blood test can separate higher-risk nodules from lower-risk ones. For a lung diagnostics company, that is basically an argument about adoption — who changes practice, who gets paid, and whether patients move faster to the right next step. ### What is Nodify Lung, exactly? Nodify Lung is Biodesix’s blood-based risk-assessment strategy for pulmonary nodules — the small spots on the lung that often show up on CT scans. The problem is that most nodules are not cancer, but some are, and clinicians have to decide who needs more imaging, biopsy, PET scanning, or just watchful follow-up. Biodesix has been building the case that its blood tests can help sort those patients earlier. (investors.biodesix.com) ### Why is that decision so hard? Because lung nodule management is full of expensive mistakes in both directions. Biodesix highlighted prior health-economics work showing that about two thirds of patients got no clinical work-up after a nodule was found, while among those who did, 60% of biopsies were done on benign nodules and 35% of malignant nodules still got a follow-up CT before diagnosis. That is the whole bottleneck in one snapshot — too much delay for some patients, too much invasive care for others. (finviz.com) ### So what changed this week? The company preannounced a slate of ATS presentations that leans hard into that bottleneck. One oral presentation looks at how prior cancer history affects a blood-based autoantibody test. The poster lineup includes real-world use of the Nodify CDT and XL2 classifiers at WVU Medicine’s Camden Clark Medical Center, plus Frederick Health Hospital work on whether a Combined Lung Cancer Identification Program, or CLIP, changed stage at diagnosis in 2022-2023. (biospace.com) ### Why do those hospital posters matter more than they sound? Because a diagnostic test does not win just by being clever. It has to fit into clinic flow. Community-hospital evidence matters because that is where scale lives. If a site can show that a blood test changes who gets worked up, who gets referred, and who gets diagnosed earlier, that is much more persuasive to health systems and payers than another abstract about assay mechanics. (investors.biodesix.com) That is also why Biodesix is pairing clinical posters with economic framing. ### What is the strongest clinical number Biodesix already has? The company’s March publication is the clearest anchor. Biodesix said a pooled retrospective analysis of more than 1,100 patients showed Nodify CDT specificity of 91% to 97% across nodule sizes and baseline risk groups, with patients drawn from 48 U.S. practices. High specificity matters here because it speaks to false positives — in plain English, how often the test wrongly pushes a benign nodule into a higher-risk bucket. (investors.biodesix.com) ### Why add a PET-versus-biomarker modeling study? Because the commercial fight is no longer just blood test versus no blood test. It is blood test versus the next-best workflow. One ATS poster asks whether clinicians should start with PET or biomarkers for indeterminate nodules, using Monte Carlo simulations and authors from Medical University of South Carolina and Vanderbilt. That is Biodesix trying to shape the care pathway itself, not just sell a test into it. (finviz.com) ### Is this really about reimbursement? A lot of it is. Last year’s company messaging around ISPOR and ATS already tied Nodify data to broader clinical adoption and payer coverage. This year’s setup looks like the next step — less “our biomarker works,” more “our program helps hospitals triage patients and may improve economics.” Turns out that is the evidence stack many diagnostics companies eventually need if they want routine use rather than curiosity. (investors.biodesix.com) ### Bottom line? Biodesix is not just pitching Nodify Lung as a smarter blood test anymore. It is pitching Nodify as a lung-nodule management system — one that can change workflow, reduce waste, and maybe catch cancers at a more treatable stage. ATS 2026 matters because that is where the company is trying to prove the harder thing. (investors.biodesix.com) (biospace.com)